A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.
This ESMO guideline is recommended to be used as the basis for treatment and management decisions, delivering a clear proposal for diagnostic and treatment measures in each stage of rectal and colon cancer and the individual clinical situations.
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas
Analysis of published data showed that the recently-described group of hypermutant, microsatellite-stable CRCs is likely to be caused by somatic POLE exonuclease domain mutations, which are predicted to impair correction of mispaired bases inserted during DNA replication.
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21
These data show that common, low-penetrance susceptibility alleles predispose to colorectal neoplasia, and suggest that susceptibility to CRC is mediated through development of adenomas.
Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer
Metastasis-associated gene expression changes can be used to refine traditional outcome prediction, providing a rational approach for tailoring treatments to subsets of patients.
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Genetic prognostic and predictive markers in colorectal cancer
- A. Walther, E. Johnstone, C. Swanton, R. Midgley, I. Tomlinson, D. Kerr
- MedicineNature Reviews. Cancer
- 1 April 2011
This work was funded by the Oxford Comprehensive Biomedical Research Centre, and the author's personal research was supported by the Wellcome Trust.
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
The usefulness of defective mismatch repair, BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy is investigated and MMR assays identify patients with a low risk of recurrence.
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk
Across the four sample sets, the association between rs4939827 and CRC was highly statistically significant (Ptrend = 1.0 × 10−12), and three SNPs in SMAD7 (involved in TGF-β and Wnt signaling) associated with CRC were identified.